Intragastric proteasome inhibition induces alpha-synuclein-immunopositive aggregations in neurons in the dorsal motor nucleus of the vagus in rats.
The neuropathological hallmark of idiopathic Parkinson's disease (PD) is dopaminergic neuron degeneration in the substantia nigra. However, it has been suggested that the neurodegenerative process initially may occur in the dorsal motor nucleus of the vagus (DMV). This implies that unidentified environmental toxins or neurotropic pathogens that is capable of passing the mucosal barrier of the gastrointestinal tract might affect the enteric nerve endings of the vagal neurons, possibly resulting in retrograde degeneration of the DMV. The present study aimed to evaluate the effects of proteasome inhibition of the intragastric nerve terminals of the DMV in rats. Following multiple injections of PSI, a selective proteasome inhibitor, or vehicle into the ventral wall of the stomach, the medulla oblongata was studied immunohistologically. In the DMV neurons of rats treated with PSI but not vehicle, alpha-synuclein-immunopositive intracytoplasmic inclusions and activated microglia were observed, predominantly in the left DMV. However, there was no significant loss of neurons. These results suggest that intragastric proteasome inhibition has a retrograde effect on DMV neurons but is insufficient to induce cell death, suggesting no causal linkage between inclusion body formation with proteasome inhibition and neuron death in the DMV. This might also implicate that Lewy body formation in the DMV in PD is possibly related to peroral invasion of environmental toxins that inhibit ubiquitin-proteasome system function.
Miwa
Hideto
H
Department of Neurology, Wakayama Medical University, 811-1 Kimiidera, Wakayama-city, Wakayama 641-8510, Japan. h-miwa@wakayama-med.ac.jp
Kubo
Tomomi
T
Suzuki
Ai
A
Kondo
Tomoyoshi
T
D000818:Animals; D004525:Efferent Pathways / Q000187:drug effects / Q000378:metabolism* / Q000503:physiopathology; D004781:Environmental Exposure; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005911:Gliosis / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology; D007150:Immunohistochemistry; D002479:Inclusion Bodies / Q000378:metabolism; D016631:Lewy Bodies / Q000187:drug effects / Q000378:metabolism; D008297:Male; D008526:Medulla Oblongata / Q000187:drug effects / Q000378:metabolism* / Q000503:physiopathology; D017628:Microglia / Q000187:drug effects / Q000378:metabolism; D009498:Neurotoxins / Q000009:adverse effects / Q000378:metabolism; D010300:Parkinson Disease / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology; D017729:Presynaptic Terminals / Q000187:drug effects / Q000378:metabolism*; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism*; D061988:Proteasome Inhibitors; D051381:Rats; D017207:Rats, Sprague-Dawley; D013270:Stomach / Q000187:drug effects / Q000294:innervation; D014630:Vagus Nerve / Q000187:drug effects / Q000378:metabolism* / Q000503:physiopathology; D051844:alpha-Synuclein / Q000378:metabolism*
D004791:Enzyme Inhibitors; D009498:Neurotoxins; D061988:Proteasome Inhibitors; D051844:alpha-Synuclein; D046988:Proteasome Endopeptidase Complex